NASDAQ:PRTA Prothena Q1 2026 Earnings Report $8.29 +0.14 (+1.72%) As of 01:24 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Prothena EPS ResultsActual EPS$0.60Consensus EPS -$0.31Beat/MissBeat by +$0.91One Year Ago EPSN/AProthena Revenue ResultsActual Revenue$51.08 millionExpected Revenue$0.81 millionBeat/MissBeat by +$50.28 millionYoY Revenue GrowthN/AProthena Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateThursday, May 7, 2026Conference Call Time4:00PM ETUpcoming EarningsProthena's Q2 2026 earnings is estimated for Monday, August 3, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Prothena Earnings HeadlinesInsider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Acquires $465,500.00 in StockJune 8, 2026 | americanbankingnews.comProthena (NASDAQ:PRTA) Upgraded to Buy at Wall Street ZenJune 6, 2026 | americanbankingnews.comRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before June 30 could reprice this stock from $2 to $20 or more within a year.June 16 at 1:00 AM | Paradigm Press (Ad)Prothena Corp. PlcMay 19, 2026 | edition.cnn.comPiper Sandler Sticks to Its Buy Rating for Prothena (PRTA)May 14, 2026 | theglobeandmail.comProthena (PRTA) Gets a Hold from RBC CapitalMay 14, 2026 | theglobeandmail.comSee More Prothena Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prothena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prothena and other key companies, straight to your email. Email Address About ProthenaProthena (NASDAQ:PRTA) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages. The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials. Additional pipeline candidates include therapies for amyloid light chain (AL) amyloidosis and other protein misfolding disorders. Prothena collaborates with global pharmaceutical partners to further develop and commercialize its product candidates, pooling resources and expertise to accelerate research timelines. Founded in 2012 as a spin-out from Elan Corporation, Prothena is headquartered in South San Francisco, California, with research operations in both the United States and Ireland. The company maintains a global focus, engaging regulators and trial sites across North America, Europe and Asia to support its clinical development programs. Prothena’s commitment to addressing high-unmet-need diseases is reflected in its strategic partnerships and research investments. Prothena is led by President and Chief Executive Officer Gene Kinney, whose experience spans decades in the pharmaceutical and biotechnology sectors. Under his leadership, the company has built a multidisciplinary team of scientists, clinicians and commercial experts. Prothena’s board and management team bring deep expertise in protein science, immunology and drug development to guide the company’s mission of bringing new treatment options to patients worldwide. View Prothena ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Lennar Finally Turning the Corner After Its Housing Slump?Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?This Golden Cross Could Send Urban Outfitters to New Highs3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Goldman’s S&P 500 Target Looks More Reachable After the Latest Rally Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
